This is a preview of subscription content, log in via an institution to check access.
Notes
The analysis was performed by GlaxoSmithKline.
Reference
Vallejo-Aparicio LA, et al. Cost-consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma. European Journal of Health Economics : 23 Sep 2019. Available from: URL: https://doi.org/10.1007/s10198-019-01101-x
Rights and permissions
About this article
Cite this article
Fluticasone furoate/vilanterol: better asthma control reduces cost. PharmacoEcon Outcomes News 838, 11 (2019). https://doi.org/10.1007/s40274-019-6256-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6256-0